Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + paclitaxel + capivasertib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Durvalumab + paclitaxel + capivasertib is an investigational triple combination regimen being studied for metastatic triple-negative breast cancer (TNBC). - **Durvalumab** is a human monoclonal antibody against programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to promote antitumor T-cell activity. - **Paclitaxel** is a chemotherapy drug that stabilizes microtubules, preventing cell division. - **Capivasertib** is a selective small molecule inhibitor of AKT, a key kinase in the PI3K/AKT pathway. The combination aims to enhance antitumor efficacy by immune checkpoint blockade, direct cytotoxicity, and targeted inhibition of cancer cell survival signaling. This regimen is under clinical investigation for first-line treatment of metastatic TNBC[4].
- Other names
- durvalumab + paclitaxel + capivasertib
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)AKT2 (Rac-beta serine/threonine-protein kinase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on durvalumab + paclitaxel + capivasertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + paclitaxel + capivasertib.